OKYO Pharma(OKYO)
LONDON, United KingdomPharmaceutical
Focus: OKYO Pharma is a London-based public company focused on small molecule therapeutics for inflammatory eye diseases and chronic pain, operating as a mid-stage biotech with a focused pipeline in immunology and ophthalmology.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About OKYO Pharma
AI assessmentNot HiringNo open roles listed right now. Follow OKYO Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
OK-101
Dry Eye DiseaseClinical Trials (1)
NCT05759208The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
Phase 2Help build intelligence for OKYO Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.